Industrial analysis.

Might be the better term for the collective “cost effectiveness” analyses of Oncotype DX evaluated in this lit review. More than half were funded by none other than Genomic Health, all of which concluded--you guessed it--unquestionable cost effectiveness via questionable methods. | Wang, J Clin Oncol 2018